Partner With Us NRI

Sanofi India Ltd share Price Today

Company details

6M Return 13.53%
1Y Return 39.41%
Mkt Cap.(Cr) 20,386.93
Volume 59,158
Div Yield 1.88%
OI Chg %
Volume 59,158

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
About The Stock

    Sanofi offers drugs in therapies like diabetes (insulins & orals), cardiology, pain, allergy and epilepsy.

    • Around 70% of sales stem from top 7 brands. Lantus, Allegra & Combiflam are in Top 100 pharmaceutical brands in India
    • Sanofi enjoys strong brand recall in anti-diabetic therapy in India

    Sanofi India reported muted numbers this quarter amid divested business and Covid sales in base year.

    • Revenues were down 11.4% YoY to ₹ 699.3 crore
    • EBITDA was at ₹ 161.1 crore, down 34.8% YoY with margins at 23%

    Consequent PAT was at ₹ 120.4 crore (down 32.5% YoY)

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Sanofi India announced Q2CY23 results:

  • The company has delivered revenue growth of 2% for Q2CY23 on a comparable basis and 12% growth in operating profits, despite the negative impact of the revised pricing for products listed in the National List of Essential Medicines.
  • Exports for Q2CY23 grew by 30% as compared to Q2CY22.
  • The profit from operations for Q2CY23 was at Rs 168 crore versus Rs 150 crore in Q2CY22, i.e., a growth of 12% while the operating margins increased from 21.5% in Q2CY22 to 23.7% in Q2CY23.
  • The improved operating margins were a result of the Company’s focus mainly on lowering expenses through overall operating efficiencies.
  • The company continues to make good progress on its ‘India for India’ strategy through go-to-market initiatives, improving operating efficiency, and promoting innovation.

Managing Director, Sanofi India, said, “The Company has delivered a strong second quarter performance despite the NLEM impact. The Company’s ‘India for India’ strategy reflects Sanofi’s ambition in the Indian Market. The Company will continue to focus on driving further improvement in operating efficiencies while expanding the availability of its established and innovative products in India.”



Result PDF

View Other Company Results

Sanofi India Ltd shares SWOT Analysis

Strengths (5)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Company with No Debt
  • Company with Zero Promoter Pledge

Weakness (3)

  • Degrowth in Quarterly Revenue and Profit in Recent Results(YoY)
  • Declining profits every quarter for the past 2 quarters
  • Fall in Quarterly Revenue and Net Profit (YoY)

Opportunity (1)

  • RSI indicating price strength

Threats (0)

Data not found

Resistance and support

R1 9,043.2
R2 9,234.5
R3 9,459.1


S1 8,627.3
S2 8,402.7
S3 8,211.4
Delivery and volume
ISHARES CORE MSCI EMERGING MARKETS ETF Block Purchase 2022-10-17 5743.7 38863 BSE
ISHARES MSCI INDIA SMALL-CAP ETF Block Purchase 2022-10-17 5743.7 4485 BSE
Name Category Shares
Hoechst Gmbh PROMOTER 60.37%


Investment recommendation
Call Date
27 Jul 2022
Entry Price 6,428.00
Target Price 6,885.00
12-18 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Sanofi India Ltd Stocks COMPARISON

Financials( in Cr) Sanofi India Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Zydus Lifesciences Ltd Divis Laboratories Ltd
Price 8,851.95 1,531.40 1,399.05 1,051.40 3,910.75
% Change 5.98 0.26 -0.54 5.45 0.47
Mcap Cr 20,386.93 367,434.16 112,954.68 105,795.44 103,818.29
Revenue TTM Cr 2,851.10 43,885.68 15,790.60 17,237.40 7,767.51
Net Profit TTM Cr 602.90 8,560.84 2,513.47 1,997.30 1,823.38
PE TTM 35.96 39.17 26.53 27.46 75.08
1 Year Return 39.41 60.69 51.61 103.07 19.36
ROCE 79.56 16.79 14.76 16.25 19.30
ROE 59.39 16.46 10.66 14.05 14.89

Equity Capital: 1,015.20 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 45,581.63 -35,822.31
LAST 3M 105,886.10 -42,131.07
LAST 6M 173,680.57 48,055.67
LAST 12M 265,486.86 128,722.00
Sanofi India Limited - Investor Presentation

May 17, 2024 l NSE Announcement

Sanofi India Limited - Loss of Share Certificates

May 16, 2024 l NSE Announcement

Sanofi India Limited - Copy of Newspaper Publication

May 15, 2024 l NSE Announcement

Date Action Type Ratio
May 03, 2024 Dividend 1170
Mar 07, 2024 Dividend 500
Apr 28, 2023 Dividend 1940

Sanofi India Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Sanofi India Limited, founded in 1956 as Hoechst Fedco Pharma Private Limited, offers therapeutic pharmaceutical products for the treatment of diabetes, cardiac and neurological conditions, and various other ailments. The company is a subsidiary of Sanofi SA (a French company), one of the leading pharmaceutical companies in the world. It has its registered office in Mumbai, Maharashtra.

    On 10 February 2023, the market capitalisation of the company was Rs 12,208.73 crore. It reported consolidated sales of Rs 2,956 crore at the end of October 2022. The company is listed on the Bombay Stock Exchange with the code 500674 and the National Stock Exchange with the code SANOFI.

    On 31 December 2022, the company’s shareholding pattern indicated a promoter stake of 60.4% with a 6.99% stake of foreign institutional investors. Mutual funds and DIIs held a consolidated stake of 19.22%, and the public held a stake of 13.9% in the company. The company’s shareholding pattern has remained largely consistent over the past year. 

    The company’s board of directors comprises Aditya Narayan, Rajaram Narayanan, Vaibhav Karandikar, Cherian Mathew, Charles Billard, Marc Antoine Lucchini, Rahul Bhatnagar, Usha Thorat, and others. The auditors are Price Waterhouse & Co Chartered Accountants LLP. On 30 September 2022, the company had a total of 2.3 crore shares outstanding.

    On 10 February 2023, Sanofi India’s share price on BSE was Rs 5,331.60 and Rs 5,331.80 on NSE. The share price touched a 52-week high of Rs 9,265.00 and a 52-week low of Rs 5,258.00. Its three-month return to investors was -5.25%, while its one-year return was -27.96%.

    On November 2022, Aditya Birla SL Frontline Equity Direct Fund-Growth invested Rs 188.97 crore in the company, while Nippon India Growth Direct-G and Nippon India Pharma Direct-G invested Rs 132.73 and Rs 130.26 crore, respectively.

     On November 2022, the company had a trailing twelve-month (TTM) revenue of Rs 2,956.60 crore. The company also had a net profit of Rs 944.40 during the same period.

    The company’s peers include Sanofi India, Abbott India, GSK Pharma, and Pfizer.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: complianceofficer@icicisecurities.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

Sanofi Hse 117-B Saki Vihar Rd, L&T Business Park Powai, Mumbai, Maharashtra, 400072

Tel : 91-22-28032000
Email : igrc.sil:sanofi.com
Website : http://www.sanofiindialtd.com

Link Intime India Pvt Ltd

AGM Date (Month) : May
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 500674
Book Closure Date (Month) : Apr/May
BSE Group : A
ISIN : INE058A01010

FAQ’s on Sanofi India Ltd Shares

You can buy Sanofi India Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Sanofi India Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 17, 2024 03:59 PM the closing price of Sanofi India Ltd was Rs.8,851.95.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 17, 2024 03:59 PM, the market cap of Sanofi India Ltd stood at Rs. 20,386.93.

The latest PE ratio of Sanofi India Ltd as of May 17, 2024 03:59 PM is 35.96

The latest PB ratio of Sanofi India Ltd as of May 17, 2024 03:59 PM is 0.05

The 52-week high of Sanofi India Ltd share price is Rs. 9,380.00 while the 52-week low is Rs. 6,256.60

According to analyst recommendations, Sanofi India Ltd Share has a "Buy" rating for the long term.

Download App

Download Our App

Play Store App Store
market app